Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imilecleucel-T - Acer Therapeutics

Next Previous
X
Search
Drug Profile

Imilecleucel-T - Acer Therapeutics

Alternative Names: Autologous T cell vaccine - Acer Therapeutics; Tcelna; Tovaxin®

Latest Information Update: 23 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Opexa Therapeutics
  • Developer Acer Therapeutics
  • Class Immunotherapies; T lymphocyte cell therapies; Vaccines
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 20 Nov 2023 Acer Therapeutics has been acquired by Zevra Therapeutics
  • 08 Aug 2019 Imilecleucel-T is still in phase II trial for Multiple sclerosis (First-line therapy) in USA, Canada (SC) (Opexa Therapeutics website, August 2017)
  • 19 Sep 2017 Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top